| 朱侃恺,于吉人,高 原.围手术期化疗治疗进展期胃癌的临床研究[J].肿瘤学杂志,2015,21(2):93-96. |
| 围手术期化疗治疗进展期胃癌的临床研究 |
| Clinical Study of Perioperative Chemotherapy for Advanced Gastric Cancer |
| 投稿时间：2014-06-03 |
| DOI：10.11735/j.issn.1671-170X.2015.02.B004 |
|
 |
| 中文关键词: 胃肿瘤 辅助化疗 预后 |
| 英文关键词:gastric neoplasms chemotherapy,adjuvant prognosis |
| 基金项目: |
|
| 摘要点击次数: 1902 |
| 全文下载次数: 882 |
| 中文摘要: |
| 摘 要：［目的］ 探讨S-1联合奥沙利铂(SOX)方案围手术期化疗治疗进展期胃癌的有效性及安全性。［方法］ 回顾性分析54例接受围手术期化疗的进展期胃癌患者的病例资料。化疗方案为：替吉奥胶囊 80mg/m2，d1~14，奥沙利铂 130mg/m2，d1，静滴，每3周重复。评价化疗有效性及安全性，根据疗效分为临床有效组与临床无效组，观察比较两组的预后。［结果］ 本组患者术前化疗2~6个周期，平均（3.6±1.2）个周期。临床有效率为57.4%，疾病控制率为96.3%，R0切除率88.9%。3年生存率为61.5%，3年无进展生存率为55.3%。临床有效组(31例)和无效组(23例)的3年生存率分别为79.6%、38.6%（P＝0.001）；3年无进展生存率分别为70.7%、34.2%（P＝0.009）。化疗期间常见的3级及以上血液毒性有血小板减少(14.8%)、白细胞减少(5.6%)；常见的3级及以上非血液毒性有恶心呕吐(3.7%)、食欲不振(3.7%)。［结论］ SOX方案围手术期化疗治疗进展期胃癌具有较高的有效率及较好的安全性，有效的围手术期化疗可改善进展期胃癌预后。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate the efficacy and safety of S-1 combined with oxaliplatin (SOX) as perioperative chemotherapy for advanced gastric cancer. ［Methods］ Data of advanced gastric cancer patients who received perioperative chemotherapy were analysed retrospectively. The chemotherapy consisted of S-1 80mg/m2 day1~14 plus oxaliplatin 130mg/m2 on day1，and the regimen was repeated every 3 weeks. The clinical response and safety were evaluated. Based on clinical response，patients were divided into response group and unresponse group. The prognosis between 2 groups was compared.［Results］ Patients received 2~6 cycles chemotherapy preoperatively，with the average cycle of 3.6. The clinical response rate and disease control rate were 57.4% and 96.3% respectively. The R0 resection rate was 88.9%.The 3-year overall survival and progression-free survival rate were 61.5% and 55.3% respectively. The 3-year overall survival rates of response group and unresponse group were 79.6% and 38.6% respectively(P=0.001). The 3-year progression-free survival rate of response group and unresponse group was 70.7% and 34.2% respectively(P=0.009). The most common grade 3/4 hematological toxicities were thrombocytopenia(14.8%) and leukocytopenia(5.6%). The most common grade 3/4 non-hematological toxicities were nausea or vomiting(3.7%) and anorexia(3.7%). ［Conclusion］ Perioperative chemotherapy with SOX has promising clinical response. It is safety as perioperative chemotherapy. Effective perioperative chemotherapy could improve the prognosis of advanced gastric cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|